English
Mankind Pharma Q2 Results
- BSE: 543904
- NSE: MANKIND
- ISIN: INE634S01028
- Sector: Biotechnology & Drugs
BSE
2,173.55
-70.35 (-3.14%)
-70.35 (-3.14%)Volume3.60 K
Updated: Fri 16 Jan, 2026 | 15:29:42
NSE
2,175.40-69.00 (-3.07%)
-69.00 (-3.07%)Volume6.30 L
Updated: Fri 16 Jan, 2026 | 15:40:00
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q2 Results Highlights
- Total Income₹3,697.16 Cr.(20.77%)
- Operating Profit₹699.51 Cr.(-6.32%)
- Profit After Tax₹511.51 Cr.(-22.01%)
- Operating Margin18.92%(-22.43%)
Note: Comparison is on YoY basis
Quarterly - Mankind Pharma Q2 Results
*All figures in crores except per share values
| Fiscal Period | Sep 25 | Jun 25 | QoQ Comp | Sep 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 2,997.65 | 2,942.26 | 1.88% | 2,314.73 | 29.50% |
| Depreciation/ Amortization | 221.82 | 218.68 | 1.44% | 100.49 | 120.74% |
| Operating Income | 699.51 | 628.09 | 11.37% | 746.70 | -6.32% |
| Net Income | 511.51 | 438.32 | 16.70% | 653.47 | -21.72% |
| Other Operating Expenses Total | 888.48 | 886.58 | 0.21% | 699.40 | 27.03% |
| Net Income Before Taxes | 624.02 | 540.49 | 15.45% | 851.23 | -26.69% |
| Total Revenue | 3,697.16 | 3,570.35 | 3.55% | 3,061.43 | 20.77% |
| Selling/ General/ Admin Expenses Total | 825.18 | 783.41 | 5.33% | 642.12 | 28.51% |
| Diluted Normalized EPS | 12.38 | 10.60 | 16.79% | 16.34 | -24.23% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.